Adaptive Biotechnologies sees 33% MRD revenue growth, boosted by new myeloma guidelines and refinancing moves

Adaptive Biotechnologies benefits from updated myeloma treatment guidelines and new definitions, establishing its clonoSEQ test as the standard for long-term MRD monitoring. The company reported a 33% year-over-year increase in MRD revenues to $66.2 million, driven by a 7% rise in clinical average selling price and a 43% jump in test volumes, resulting in a 14% adjusted EBITDA margin. Additionally, refinancing a $345 million zero-coupon note and eliminating the OrbiMed revenue share have extended the company's financial runway beyond five years and removed a significant growth tax. Despite a premium valuation of about 14 times EV/Sales, this is supported by strong recurring revenues, high incremental margins, and the planned separation of its Immune Medicine segment.

Adaptive Biotechnologies (ADPT) trades at USD 26.59 on Pluang as of Oct 27, 2026 21:31 WIB, showing a modest 1.22% gain in the last day. Despite strong revenue growth and strategic refinancing reported recently, Pluang users are predominantly selling, with 99% of order activity on the platform being sell orders. The stock remains well below its 52-week high of USD 29.84, indicating cautious sentiment among investors on Pluang.